Research Progress of Immune Heterogeneity in Leukemia Microenvironment--Review.
10.19746/j.cnki.issn.1009-2137.2023.05.050
- Author:
Feng LI
1
;
Fei-Fei YANG
2
;
Yan-Li XU
3
Author Information
1. Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China.
2. Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China.E-mail: lydia9017@sina.com.
3. Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China.E-mail: xuyanli62@sohu.com.
- Publication Type:Journal Article
- Keywords:
immune heterogeneity;
leukemia;
microenvironment
- MeSH:
Humans;
Immunotherapy/methods*;
Leukemia/therapy*;
Immunity;
Combined Modality Therapy;
Prognosis;
Tumor Microenvironment
- From:
Journal of Experimental Hematology
2023;31(5):1569-1573
- CountryChina
- Language:Chinese
-
Abstract:
Although the body has a strong immune system which can resists the invasion of leukemia cells, leukemia cells disseminate systemically and form an immunosuppressive microenvironment through a variety of mechanisms, including regulation of antigen presentation, utilization of immunosuppressive enzyme AXL, immune cell inhibitory checkpoint NKG2A and immunoregulatory gene VISTA, resulting in immune escape. Therefore, most types of leukemia are inevitable for the affliction of drug resistance or relapse, and the immune efficacy is not as significant as that of other hematological tumors and the prognosis is suboptimal. This article reviews the immune heterogeneity of leukemia microenvironment from many aspects, including anti-leukemia immunity and immune escape. In addition, it also reviews the latest progress and future prospects of immune checkpoint inhibition, adoptive cell therapy and vaccine therapy in leukemia, providing a theoretical basis for the development of personalized combination therapy strategies with less toxic side effects.
